Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Kawasaki DiseasePilot StudyCoronary Artery AneurysmRivaroxaban

Interventions

DRUG

Rivaroxaban (Xarelto)

Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model-informed dose optimization study

Trial Locations (1)

RECRUITING

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors

lead

Children's Hospital of Fudan University

OTHER